{
  "docId": "019de071-a0aa-74fc-b780-f72cc7f02158",
  "docSlug": "6af314fff9e6eaaf966098f4c73a6229",
  "documentTitle": "Mink Therapeutics | IPO Presentation Deck | 36 slides",
  "authorId": "mink-therapeutics",
  "authorName": "MiNK Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7860465,
  "pageNumber": 6,
  "pageCount": 36,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "unfair_advantage",
  "function": "other",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide highlights specific financial figures ($50mm investment, $800mm in transactions) as evidence of the parent company's support.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/6",
  "deckHref": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158",
  "deckJsonHref": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json",
  "deckAnchorHref": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "Agenus’ significant investment in the MiNK platform – ~$50mm to date as of June 30, 2021\nFoundational leadership at MiNK with key scientific and clinical achievements at Agenus since 2015 - advanced 17 discoveries to the clinic and secured ~$800mm in upfront and milestone payments and equity investments through partnering transactions\nExperts in iNKT cell biology and antibody engineering applicable to iNKT (e.g., CAR, iNKT engagers) with a record of success in delivering now-BLA stage antibodies at Agenus\nAccess to combination antibodies (PD-1, CTLA-4, TIGIT, etc) through Agenus’ pipeline of immuno-oncology antibodies and immune stimulating adjuvants\nExperienced cGMP manufacturing team and existing manufacturing facilities de-risks and differentiates from capital-intensive cell therapy companies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cdb5be9e-313b-409b-b3a7-e89cf41f0f6c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "MiNK Is Favorably Positioned through its Roots in Agenus",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1be4060c-d713-464e-9703-ee944b4729c6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 36,
      "from": 5,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b",
      "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.",
      "position": 0,
      "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}